Most Popular Products
CRISPR Gene Editing
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein Purification
Proteins
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
Market Leader for Optimized Production
Explore our next-generation saRNA templates (patent filed) optimized for in vitro and in vivo expression profiles to support applications from immunization to in vivo CAR therapies
Enhanced & Prolonged Expression
Less quantity needed for strong and lasting expression
Optimized Vectors for Diverse Applications
Vectors with varying degrees of immunogenicity available for different applications
| Vector Name | Capping type | Modification | in vitro expression | in vivo targeting | ||
|---|---|---|---|---|---|---|
| HEK293T | A549 | Jurkat | ||||
| GS-saRNA-1 (Vector for saRNA catalog products) |
Cap-AU | m5C | ++++ | +++ | +++ | spleen, heart, kidney |
| GS-saRNA-3 | Cap-AU | m5C or None | +++++ | +++ | + | spleen, lymph node |
| GS-saRNA-4 | Cap-AU | m5C or None | ++++ | +++ | +++ | Spleen |
GS-saRNA-1: High expression across multiple cell lines with broad in vivo distribution. Recommended as a versatile vector for routine use, including immunization and protein replacement therapy.
GS-saRNA-3: Strong in vitro expression in non-immune cell lines; low expression in immune cells. Ideal for applications targeting non-immune cell lines with spleen-specific in vivo activity.
GS-saRNA-4: Comparable in vitro expression to GS-saRNA-1, with distinct in vivo distribution—primarily in the spleen.
GenScript saRNA offers the flexibility to meet your project needs
GS-saRNAs demonstrate similar or even higher expression levels at lower doses compared to generic mRNA or circRNA.
EGFP mRNA, circRNA, or saRNA were transfected into HEK293T, A549, or Jurkat cells using LNP (SM102). The EGFP signal was visualized using fluorescence microscopy and quantified with ImageJ software at 24, 48, and 72 hours post-transfection.
EGFP mRNA, circRNA, or saRNA were transfected into A549 cells using LNP (SM102). Immunogenicity-related cytokines, including IL6, IFN-α, and IP-10, were assessed using an ELISA assay at 48h post-transfection.
In vivo expression of GS-saRNA in mouse
SaRNA have longer expression than linear mRNA in vivo; No significant toxicity was observed.
LNP encapsulate (SM102) Fluc mRNA or saRNA were intravenously injected into mice at a dose of 0.25 mg/kg. N=3 per group. 24 hours after injection, mice received an intraperitoneal injection of 100 μL of 30 mg/mL D-luciferin, mice were subjected to imaging using the In Vivo Imaging System to evaluate total luminescence. Mice were subjected to continuously detection of total luminescence at different time point.
In vivo distribution of GS-saRNA in mouse
In contrast to mRNAs, which are mainly expressed in the liver, saRNAs exhibit extrahepatic expression.
LNP encapsulate (SM102) Fluc mRNA or saRNA were intravenously injected into mice at a dose of 0.25 mg/kg. N=3 per group. 24 hours after injection, mice received an intraperitoneal injection of 100 μL of 30 mg/mL D-luciferin, mice were subjected to imaging using the In Vivo Imaging System to evaluate total luminescence. After that, mice were sacrificed, distribution of luminescence across brain, heart, lungs, liver, kidneys, lymph node and spleen were imaged and quantified.
| QC | Item | Test Method | Specification | RUO Standard |
RUO Upgrade |
|---|---|---|---|---|---|
| Identification | Appearance | Visual inspect | Clear and free of foreign particles | ||
| RNA length | Capillary electrophoresis | Target ± 30% | |||
| RNA length | Agarose gel electrophoresis | Expected size band detected | |||
| Poly(A) length | Enzyme digestion and CE | Target ± 30% | |||
| RNA content | UV absorbance | Target ± 5% | |||
| PH | pH meter | Target ± 0.5 | |||
| Buffer specification | Client spec | N/A | |||
| Purity | A 260/280 ratio | UV spec | 1.70 ~ 2.30 | ||
| Capping efficiency | LC-MS | ≥ 90% | |||
| Size-based purity | Capillary electrophoresis | ≥ 70% | |||
| Safety | Endotoxin | Semiquantitative | < 10 EU/mg |
100ng of GS-saRNA-1 or GS-saRNA-2 vector based eGFP saRNA (5-methylcytidine) were transferred into HEK293T cells using LNP or Lipofectamine MessengerMAX (Thermo Fisher). 24 and 48h after transfection, eGFP expression is observed by fluorescence microscopy.
The expression of GS-saGLuc (GenScript, based on GS-saRNA-1 vector, 5-methylcytidine) is compared with that of customer-designed saGLuc (Client). The Results show that GS-saGLuc have higher initial expression and sustained expression (over 10 folds) than customer-designed saGLuc. Left: Luciferase activity at 12, 24, 48, 96 and 144h after transfection; Right: Fold change of Gluc level, normalizated by the value of Client.
Learn about key structural components of saRNA, the processes by which saRNA replicates and is translated into protein, and more.
Free Download
Systematic Screening and Engineering Enhances Superior Protein Expression and Organ-Specific Targeting for RNA Therapeutics
Download ArticleSelf-amplifying mRNAs derived from the genomes of positive-strand RNA viruses, it is a type of synthetic RNA that has been engineered to replicate itself once inside a cell. SaRNA contains the virus replicase genes encoding an RNA-dependent RNA polymerase (RdRP) complex, which amplifies synthetic transcripts in situ.
They are both linear mRNA, saRNA encodes 5′ and 3′ UTR sequences, the nsP1-4 genes, a subgenomic promoter, and the protein-encoding sequence. Following in situ translation, the nsP1-4 proteins form an RdRP complex which recognizes flanking UTR sequences and amplifies PROTEIN-encoding transcripts. This results in an accumulation of the antigen or immunotherapy within the cell.
During the replication process, saRNA forms a dsRNA structure, which induces a strong natural immune response in the host cells, giving saRNA a natural advantage and great potential for application in the field of immunotherapy.
Because the length of nsp1-4 is over 7k, so the optimal length of GOI is 400 bp-6kb. If you need to synthesize shorter or longer saRNA, please consult our technical team.
For RUO grade, we use Column purification or LiCl precipitation to ensure high purity of mRNA; for Preclinical grade, we use oligo-DT chromatography.
5-methylcytidine is a suitable base modification for saRNA. Base modification for saRNA should be picked carefully as the expression of saRNA will be affected.
We use Cap 1 in our saRNA.
We offer 3 options : 1mM sodium citrate, TE pH7, and RNase-Free H2O. 1mM sodium citrate is our default option for better saRNA stability.
Yes. We have our patented backbone for saRNA.
The vector we used for saRNA contains ~70A.
saRNA have good stability when stored at -20℃, up to 24 weeks.
Yes, GenScript offers GenCap AU and AG.
It is not a VEEV vector, but from a virus very evolutionary close to VEEV virus. If you want to use VEEV replicon vector, we also have optimized design for that to provide. However, our patented saRNA vector expression is much better.
High-quality custom mRNA production via our proprietary IVT RNA manufacturing workflow.
Learn More
Our off-the-shelf mRNA is optimized with 5’ cap and polyA tails that is ready to use for your research needs
Learn More
Circular RNA offers improved stability and longer expression duration.
Learn More
LNP Packaging
Learn More
